UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
000-55016 |
26-0690857 |
(State or other jurisdiction of
incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
655 Montgomery Street, Suite 900
San Francisco, CA |
94111 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement
On January 13, 2014, Amarantus Bioscience
Holdings, Inc. (the “Company”) entered into a securities purchase agreement pursuant to which the Company agreed to
issue 1,111.11 shares of its Series E Convertible Preferred Stock (”Series E Preferred Stock”) for gross proceeds
of $1,000,000 bringing the total amount received by the Company from the sale of its Series E Preferred Stock to an aggregate
of $6,000,000.
On January 13, 2015, the Company filed a
Certificate of Amendment to the Certificate of Designation to its Series E Convertible Preferred Stock to increase the number of
Series E Preferred stock to 7,233 shares of Series E Preferred Stock.
The sale of the shares of the Series E Preferred
Stock were made upon the same terms and conditions of the Series E Preferred Stock transaction previously disclosed by the Company
in its current reports on Form 8-K filed with the Securities and Exchange Commission on November 14, 2014 and December 24, 2014.
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 is
incorporated by reference herein.
The issuance of the securities described
above were completed in accordance with the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended.
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
The information set forth in Item 1.01 is
incorporated by reference herein.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
3.1
|
|
Certificate of Amendment to Certificate of Designation of Series E Preferred Stock filed January 13, 2014 |
|
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
Date: January 14, 2015 |
|
By: |
/s/ Gerald E. Commissiong |
|
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
|
Title: Chief Executive Officer |
|
Exhibit 3.1
|
BARBARA
K. CEGAVSKE
Secretary
of State
202
North Carson Street
Carson
City, Nevada 89701-4201
(775)
684-5708
Website:
www.nvsos.gov |
|
|
|
Filed in the office of |
Document Number |
Amendment
to |
|
|
20150014181-03 |
Certificate
of Designation |
|
Barbara K. Cegavske |
Filing Date and Time |
After
Issuance of Class or Series |
|
Secretary of State |
01/13/2015 10:16 AM |
(PURSUANT
TO NRS 78.1955) |
|
State of Nevada |
Entity Number |
|
|
|
E0146522013-6 |
USE BLACK INK ONLY - DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate
of Amendment to Certificate of Designation For Nevada Profit Corporations
(Pursuant
to NRS 78.1955 - After issuance of Class or Series)
1. Name
of corporation:
Amarantus
Bioscience Holdings, Inc.
2. Stockholder
approval pursuant to statute has been obtained.
3. The
class or series of stock being amended:
Series
E Convertible Preferred Stock
4. By
a resolution adopted by the board of directors, the certificate of designation is being amended as follows or the new class or
series is:
The
third Whereas clause of the Certificate of Designation of the Corporation for the Series E Convertible Preferred Stock shall be
deleted in its entirety and replaced with the following.
WHEREAS,
it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preference, restrictions
and other matters relating to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Purchase
Agreement, up to 7,223 shares of the preferred stock which the Corporation has the authority to issue, as follows:
5. Effective
date of filing: (optional)
(must
not be later than 90 days after the certificate is filed)
6. Signature:
(required)
/s/ Marc Faerber |
|
Signature of Officer |
|
Filing
Fee: $175.00
IMPORTANT:
Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
This
form must be accompanied by appropriate fess. |
|
Nevada Secretary of State NRS Amend Designation – After |
|
|
Revised:
1-5-15 |
CERTIFICATE OF AMENDMENT OF
CERTIFICATE OF DESIGNATION OF
AMARANTUS
BIOSCIENCE HOLDINGS, Inc.
Pursuant to Section 78.1955 of the
Nevada Revised Statutes
SERIES E CONVERTIBLE PREFERRED STOCK
On behalf of Amarantus
BioScience Holdings, Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies that the
following resolution has been duly adopted by the board of directors of the Corporation (the “Board”):
RESOLVED, that, pursuant
to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Corporation (the
“Articles of Incorporation”):
| 1. | The third Whereas clause of the Certificate of Designation of the Corporation for the Series E
Convertible Preferred Stock shall be deleted in its entirety and replaced with the following: |
WHEREAS, it is the desire of
the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters
relating to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Purchase Agreement, up
to 7,223 shares of the preferred stock which the Corporation has the authority to issue, as follows:
| 2. | Section 2 of the Certificate of Designation of the Corporation for the Series E Convertible Preferred
Stock shall be deleted in its entirety and replaced with the following: |
Section
2. Designation, Amount and Par Value. The series of preferred
stock shall be designated as its Series E 12% Convertible Preferred Stock (the “Preferred Stock”) and the number
of shares so designated shall be up to 7,223 (which shall not be subject to increase without the written consent of all of the
holders of the Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each
share of Preferred Stock shall have a par value of $0.001 per share and a stated value equal to $1,000, subject to increase set
forth in Section 3 below (the “Stated Value”).
IN WITNESS WHEREOF,
the undersigned have duly signed this Certificate of Amendment to the Certificate of Designation of the Series E Convertible Preferred
Stock as of this 13th day of January 2015.
Amarantus BioScience Holdings, Inc. |
|
|
|
/s/ Marc Faerber |
|
By: Marc Faerber |
|
Title: Secretary and V.P. Finance |
|
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024